Covid hospitalizations spike with new variant as school returns, U.S. readies vaccines

Covid hospitalizations spike with new variant as school returns, U.S. readies vaccines


Medical staff treat a coronavirus disease (COVID-19) patient in their isolation room on the Intensive Care Unit (ICU) at Western Reserve Hospital in Cuyahoga Falls, Ohio, U.S., January 4, 2022.

Shannon Stapleton | Reuters

Covid hospitalizations are increasing substantially across much of the U.S. for the first time this year, just as students are returning to school and shortly before updated shots arrive at pharmacies for a fall vaccination campaign.

New hospitalizations have jumped about 16% in the U.S. over the past week, continuing an upward trend that began in late July, according to data from the Centers for Disease Control and Prevention.

New hospital admissions spiked more than 30% over the past week in Arkansas, Colorado, Indiana, Kansas, Minnesota, Oklahoma, Tennessee, Utah and Wyoming, according to the data.

The late summer Covid spike comes after a quiet year in which hospitalizations and deaths declined week after week since January.

Dr. Deborah Birx, former White House coronavirus response coordinator during the Trump administration, said the U.S. has largely let its guard down and is ignoring the summer wave of infections, despite the fact that the virus is following a predictable pattern the nation has been through ever year of the pandemic.

“We’re living in a bit of a fantasy world where we’re pretending Covid is not relevant,” Birx told ABC in a podcast interview last week. “There is a lot of Covid out there and we’re not testing for it and we’re not telling people to get tested,” she said.

CNBC Politics

Read more of CNBC’s politics coverage:

The U.S. is rolling out updated shots from Pfizer, Moderna and Novavax later this month for a fall vaccination campaign, but the public health response is still struggling to keep up with a fast-evolving virus. The shots were designed months ago to target a variant, XBB.1.5, that is no longer dominant.

Birx said those vaccines should have been released weeks ago to combat the predictable summer wave, and the U.S. should already be developing new shots for January to target the emerging BA.2.86 variant.

Scientists in China conducted lab studies that found BA.2.86 has a large number of mutations that allow the variant to dodge the protection conferred by vaccination or previous infection. BA.2.86 has been detected in 11 countries in small numbers, including the U.S., so far.

“This booster is most likely not going to work with the winter wave because we already have a pretty significant escape variant out there,” Birx said.

Subsequent studies indicated BA.2.86 may not be as immune evasive as originally feared. Moderna said Wednesday its updated shot produced a strong immune response against BA.2.86 during a clinical trial.

The CDC, in a risk assessment published last month, said BA.2.86 may be more adept at causing infection but there’s no evidence the variant results in more severe illness. The updated shots should be effective at reducing severe disease and hospitalization from the variant, according to the agency.

White House Press Secretary Karine Jean-Pierre said on Tuesday that the Biden administration believes the U.S. is well prepared with shots, antivirals and at-home tests heading into the fall and winter.

‘It’s not going to be a tsunami’

Though Covid is on the rise again, Dr. Anthony Fauci said the number of hospitalizations and deaths are low and the U.S. has a substantial wall of immunity from vaccination and prior infection.

“I doubt very seriously whether you’re going to see the hospital and death surge that we’ve seen in the past even if we get a surge of infections because there’s enough fundamental, community-level protection,” Fauci told the BBC in an interview last week.

“It’s not going to be the tsunami of cases that we’ve seen,” said Fauci, who stepped down last year from his role as head of the National Institute of Allergy and Infectious Diseases and White House chief medical advisor.

Still, the rise in Covid transmission is causing some disruption in communities. Some school districts in Kentucky and Texas recently canceled classes due to a surge in respiratory illnesses.

And the virus struck the White House again with first lady Jill Biden testing positive this week and showing mild symptoms. President Joe Biden, who is attending the G20 summit in India this week, has tested negative. The first lady last caught Covid in August 2022 and the president tested positive in July of last year.

Birx said it was a “huge mistake” for the CDC to stop tracking cases after the public health emergency ended and rely mostly on hospitalization data to monitor how the virus is spreading: “By the time you see hospitalizations in your area, the virus has been circulating for four to six weeks,” she said.

Birx said the summer wave comes about two weeks later every year, which means the U.S. should expect a winter surge in late December or early January: “We should be making vaccine right now for that wave,” she told ABC.

Current Covid strain less pathogenic than delta variant, says Dr. Scott Gottlieb





Source

Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
Health

FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images U.S. cattle ranchers will soon have a new […]

Read More